Page 112 - GHES-2-4
P. 112
Global Health Economics and
Sustainability
Cost-effectiveness of oral semaglutide in Greece
Figure 2. Number needed to treat (PIONEER 2). Figure created using Microsoft Excel
Figure 3. Number needed to treat (PIONEER 3). Figure created using Microsoft Excel
Figure 4. Number needed to treat (PIONEER 4). Figure created using Microsoft Excel
3.3. Cost per patient achieving treatment targets higher than that of empagliflozin 25 mg across all
Based on PIONEER 2, the cost per patient achieving assessed outcomes (Figure 5). Specifically, for the targets
treatment targets with oral semaglutide 14 mg was of HbA1c ≤6.5% and HbA1c <7%, the cost difference
Volume 2 Issue 4 (2024) 5 https://doi.org/10.36922/ghes.3032
